WO2004074516A2 - モノクローナル抗体製剤の奏効性を向上させる方法 - Google Patents
モノクローナル抗体製剤の奏効性を向上させる方法 Download PDFInfo
- Publication number
- WO2004074516A2 WO2004074516A2 PCT/JP2004/001822 JP2004001822W WO2004074516A2 WO 2004074516 A2 WO2004074516 A2 WO 2004074516A2 JP 2004001822 W JP2004001822 W JP 2004001822W WO 2004074516 A2 WO2004074516 A2 WO 2004074516A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- monoclonal antibody
- amino acid
- acid sequence
- patient
- sequence
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims description 39
- 238000000034 method Methods 0.000 title claims description 33
- 230000002708 enhancing effect Effects 0.000 title 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 64
- 108091007433 antigens Proteins 0.000 claims description 40
- 102000036639 antigens Human genes 0.000 claims description 40
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 33
- 239000000427 antigen Substances 0.000 claims description 33
- 108090000623 proteins and genes Proteins 0.000 claims description 31
- 208000031886 HIV Infections Diseases 0.000 claims description 29
- 230000027455 binding Effects 0.000 claims description 27
- 238000009739 binding Methods 0.000 claims description 22
- 102000004169 proteins and genes Human genes 0.000 claims description 19
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 18
- 230000004044 response Effects 0.000 claims description 11
- 230000009257 reactivity Effects 0.000 claims description 9
- 150000007523 nucleic acids Chemical group 0.000 claims description 7
- 239000012472 biological sample Substances 0.000 claims description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 5
- 230000004043 responsiveness Effects 0.000 claims description 2
- 102000003886 Glycoproteins Human genes 0.000 claims 1
- 108090000288 Glycoproteins Proteins 0.000 claims 1
- 230000004071 biological effect Effects 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 description 13
- 108020004414 DNA Proteins 0.000 description 12
- 230000003472 neutralizing effect Effects 0.000 description 11
- 239000002773 nucleotide Substances 0.000 description 11
- 125000003729 nucleotide group Chemical group 0.000 description 11
- 241000700605 Viruses Species 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 102000007079 Peptide Fragments Human genes 0.000 description 5
- 108010033276 Peptide Fragments Proteins 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 4
- 102100034349 Integrase Human genes 0.000 description 4
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 102100026189 Beta-galactosidase Human genes 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 3
- 102000003992 Peroxidases Human genes 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 108010005774 beta-Galactosidase Proteins 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 108040007629 peroxidase activity proteins Proteins 0.000 description 3
- 210000004180 plasmocyte Anatomy 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000036436 anti-hiv Effects 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 108700020302 erbB-2 Genes Proteins 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 230000000984 immunochemical effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 1
- 101710121417 Envelope glycoprotein Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 101150054472 HER2 gene Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 102100022563 Tubulin polymerization-promoting protein Human genes 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- FHIVAFMUCKRCQO-UHFFFAOYSA-N diazinon Chemical compound CCOP(=S)(OCC)OC1=CC(C)=NC(C(C)C)=N1 FHIVAFMUCKRCQO-UHFFFAOYSA-N 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 238000012151 immunohistochemical method Methods 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000007857 nested PCR Methods 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- -1 polyethylene Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000001566 pro-viral effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000010971 suitability test Methods 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/546,293 US8332159B2 (en) | 2003-02-20 | 2004-02-18 | Method for enhancing efficacy of preparation of monoclonal antibody |
EP04712210.6A EP1595959B1 (en) | 2003-02-20 | 2004-02-18 | Method for enhancing efficacy of a monoclonal antibody preparation |
JP2005502742A JP4922613B2 (ja) | 2003-02-20 | 2004-02-18 | モノクローナル抗体製剤の奏効性を向上させる方法 |
ES04712210.6T ES2528738T3 (es) | 2003-02-20 | 2004-02-18 | Método para potenciar la eficacia de una preparación de un anticuerpo monoclonal |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003-042819 | 2003-02-20 | ||
JP2003042819 | 2003-02-20 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004074516A2 true WO2004074516A2 (ja) | 2004-09-02 |
WO2004074516A1 WO2004074516A1 (ja) | 2004-09-02 |
Family
ID=
Non-Patent Citations (1)
Title |
---|
NIPPON RINSHO, vol. 60, no. 3, 2002 |
Also Published As
Publication number | Publication date |
---|---|
US20060280751A1 (en) | 2006-12-14 |
EP1595959A1 (en) | 2005-11-16 |
ES2528738T3 (es) | 2015-02-12 |
JP4922613B2 (ja) | 2012-04-25 |
US8332159B2 (en) | 2012-12-11 |
EP1595959B1 (en) | 2015-01-21 |
PT1595959E (pt) | 2015-03-05 |
JPWO2004074516A1 (ja) | 2006-06-01 |
EP1595959A4 (en) | 2006-06-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2367901C (en) | Monoclonal antibodies, antigens and diagnosis and therapy of malignant diseases | |
JP2002533056A (ja) | 肺癌の治療および診断のための化合物および方法 | |
CN110684740B (zh) | 一种抗人泛素羧基末端水解酶-1(uch-l1)的单克隆抗体及其应用 | |
EP2238167B1 (en) | Anti-t. cruzi antibodies and methods of use | |
KR20020007362A (ko) | 유방암의 면역요법 및 진단용 화합물 및 이의 사용 방법 | |
CN113121678B (zh) | 一种抗hiv-1 p24的重组抗体 | |
KR20090015034A (ko) | 가용성 바이러스-특이적 t-세포 수용체의 조성물 | |
JP4922613B2 (ja) | モノクローナル抗体製剤の奏効性を向上させる方法 | |
US20160053005A1 (en) | Methods for diagnosing and treatment of breast cancer and pharmaceutical composition and kit for same | |
EP2893349B1 (en) | Methods for identifying hiv neutralizing antibodies | |
JP5218943B2 (ja) | 特発性肺線維症の検出マーカー、検出キット及び検出方法 | |
JPH04126085A (ja) | ネコ免疫不全ウイルスの遺伝子rnaに相補性を示すdna | |
JP2885689B2 (ja) | ヒト内在性レトロウイルス遺伝子由来のポリペプチドまたは該ポリペプチドに対する抗体からなる癌検出剤 | |
EP3919503A1 (en) | Method for identifying helicobacter pylori strain and kit for identification | |
EP4274617A1 (en) | An agr2xcd3 bispecific engager for the treatment of cancer | |
TWI249407B (en) | Hybridoma cell line for producing monoclonal antibody against porcine endogenous retrovirus envelope protein and the produced monoclonal antibody and their use | |
CN116813764A (zh) | 一种白色念珠菌人源化抗体的制备方法 | |
US7928188B2 (en) | Antigen polypeptide for the diagnosis and/or treatment of ovarian cancer | |
KR100477898B1 (ko) | 인간 CacyBP/SIP에 대한 단일클론 항체 및 이를생산하는 융합세포주 | |
CN117683129A (zh) | 全人源抗鼠疫耶尔森菌中和性抗体及其制备方法和用途 | |
CN116253796A (zh) | 靶向冠状病毒的中和抗体、其抗原结合片段及其用途 | |
KR20000071901A (ko) | 유전자치료용 바이러스에 대한 항체 진단용 키트 | |
JP2003194814A (ja) | 強皮症の診断薬 | |
WO1998033938A1 (en) | Materials and methods relating to the identification of a polymorphism associated with disease susceptibility | |
JPH09188699A (ja) | ネコ免疫不全ウイルス(fiv)キャプシド抗原に対するモノクローナル抗体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004712210 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005502742 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006280751 Country of ref document: US Ref document number: 10546293 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2004712210 Country of ref document: EP |
|
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWP | Wipo information: published in national office |
Ref document number: 10546293 Country of ref document: US |